Chromogranin-A and N-terminal pro-brain natriuretic peptide: An excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4293-4299

  Korse, Catharina M ^a   Taal, Babs G ^a   De Groot, Cornelis A ^a   Bakker, Robert H ^a   Bonfrer, Johannes M G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CHROMOGRANIN A; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD SAMPLING; CARCINOID SYNDROME; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; TRICUSPID VALVE REGURGITATION; ULTRASOUND; AGED; BLOOD; IMMUNORADIOMETRIC ASSAY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL;

AGED; BIOLOGICAL MARKERS; CARCINOID HEART DISEASE; CHROMOGRANIN A; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NEUROENDOCRINE TUMORS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 70349328339     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.7047     Document Type: Article

References (49)

1. Quaedvlieg PF, Visser O, Lamers CB, et al: Epidemiology and survival in patients with carcinoid disease in The Netherlands: An epidemiological study with 2391 patients. Ann Oncol 12:1295-1300, 2001
2. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1:238-239, 1963
3. Vinik AI, Gonin J, England BG, et al: Plasma substance-P in neuroendocrine tumors and idio-pathic flushing: The value of pentagastrin stimulation tests and the effects of somatostatin analog. J Clin Endocrinol Metab 70:1702-1709, 1990
4. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 10:459-462, 2003
5. Bajetta E, Ferrari L, Martinetti A, et al: Chromogranin A, neuron specific enolase, carcino-embryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86:858-865, 1999
6. Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion 62:33-38, 2000 (suppl 1)
7. Sondenaa K, Sen J, Heinle F, et al: Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: Preliminary report. World J Surg 28:890-895, 2004
8. Korse CM, Bonfrer JM, Aaronson NK, et al: Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 89:296-301, 2009
9. Degorce F, Goumon Y, Jacquemart L, et al: A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 79:65-71, 1999
10. Robiolio PA, Rigolin VH, Wilson JS, et al: Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92:790-795, 1995
11. Ross EM, Roberts WC: The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 79:339-354, 1985
12. Thorson A, Biorck G, Bjorkman G, et al: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis: A clinical and pathologic syndrome. Am Heart J 47:795-817, 1954
13. Westberg G, Wangberg B, Ahlman H, et al: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 88:865-872, 2001
14. Zuetenhorst JM, Bonfrer JM, Korse CM, et al: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 97: 1609-1615, 2003
15. Pellikka PA, Tajik AJ, Khandheria BK, et al: Carcinoid heart disease: Clinical and echocardiographic spectrum in 74 patients. Circulation 87: 1188-1196, 1993
16. Strickman NE, Rossi PA, Massumkhani GA, et al: Carcinoid heart disease: A clinical pathologic, and therapeutic update. Curr Probl Cardiol 6:1-42, 1982
17. Kinnunen P, Vuolteenaho O, Ruskoaho H: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 132:1961-1970, 1993
18. Epstein M, Loutzenhiser R, Friedland E, et al: Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. J Clin Invest 79:738-745, 1987
19. de Bold AJ: Atrial natriuretic factor: A hormone produced by the heart. Science 230:767-770, 1985
20. Valli N, Gobinet A, Bordenave L: Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 134:437-444, 1999
21. Bay M, Kirk V, Parner J, et al: NT-proBNP: A new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 89:150-154, 2003
22. Boerrigter G, Burnett JC Jr: Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 13:643-652, 2004
23. Geiger R, Hammerer-Lercher A, Url C, et al: NT-proBNP concentrations indicate cardiac disease in pediatric patients. Int J Cardiol 123:63-65, 2007
24. Hunt PJ, Richards AM, Nicholls MG, et al: Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 47:287-296, 1997
25. Connolly HM, Pellikka PA: Carcinoid heart disease. Curr Cardiol Rep 8:96-101, 2006
26. Baudin E, Gigliotti A, Ducreux M, et al: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78:1102-1107, 1998
27. Giovanella L, La Rosa S, Ceriani L, et al: Chromogranin-A as a serum marker for neuroendocrine tumors: Comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 14:160-166, 1999
28. Prontera C, Emdin M, Zucchelli GC, et al: Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: Comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42:37-44, 2004
29. Cowie MR, Jourdain P, Maisel A, et al: Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24:1710-1718, 2003
30. Zuetenhorst JM, Korse CM, Bonfrer JM, et al: Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 90:2073-2079, 2004
31. Clerico A, Fontana M, Zyw L, et al: Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: A systematic review. Clin Chem 53: 813-822, 2007
32. Jensen EH, Kvols L, McLoughlin JM, et al: Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 14:780-785, 2007
33. Taal BG, Smits M: Developments in diagnosis and treatment of metastatic midgut carcinoid tumors: A review. Minerva Gastroenterol Dietol 51: 335-344, 2005
34. Moller JE, Connolly HM, Rubin J, et al: Factors associated with progression of carcinoid heart disease. N Engl J Med 348:1005-1015, 2003
35. Zuetenhorst JM, Taal BG: Carcinoid heart disease. N Engl J Med 348:2359-2361, 2003
36. Frojd C, Larsson G, Lampic C, et al: Health related quality of life and psychosocial function among patients with carcinoid tumours: A longitudinal, prospective, and comparative study. Health Qual Life Outcomes 5:18, 2007
37. McKee PA, Castelli WP, McNamara PM, et al: The natural history of congestive heart failure: The Framingham study. N Engl J Med 285:1441-1446, 1971
38. Clerico A, Del Ry S, Maffei S, et al: The circulating levels of cardiac natriuretic hormones in healthy adults: Effects of age and sex. Clin Chem Lab Med 40:371-377, 2002
39. Raymond I, Groenning BA, Hildebrandt PR, et al: The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745-751, 2003
40. Clerico A, Iervasi G, Pilo A: Turnover studies on cardiac natriuretic peptides: Methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 1:85-105, 2000
41. Felker GM, Petersen JW, Mark DB: Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 175:611-617, 2006
42. Bruins S, Fokkema MR, Romer JW, et al: High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50:2052-2058, 2004
43. Melzi dG, Tagnochetti T, Nauti A, et al: Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 49:1554-1555, 2003
44. Wu AH, Smith A, Wieczorek S, et al: Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628-631, 2003
45. Wu AH: Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of results. Am Heart J 152:828-834, 2006
46. Anderson AS, Krauss D, Lang R: Cardiovascular complications of malignant carcinoid disease. Am Heart J 134:693-702, 1997
47. Modlin IM, Latich I, Kidd M, et al: Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 4:526-547, 2006
48. Denney WD, Kemp WE Jr, Anthony LB, et al: Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 32:1017-1022, 1998
49. Moller JE, Pellikka PA, Bernheim AM, et al: Prognosis of carcinoid heart disease: Analysis of 200 cases over two decades. Circulation 112:3320-3327, 2005